Page 2 - Base Editing News Today

BioPharma

Modifying a patient’s DNA is no longer just for science fiction novels. The CRISPR gene editing technique developed by Jennifer Doudna and Emmanuelle Charpentier only took 10 years to reach the market as Casgevy (exagamglogene autotemcel/exa-cel, Vertex Pharmaceuticals Inc.), treating congenital pathologies such as β-thalassemia and severe sickle cell disease (SCD). But science does not stop.

Sickle cell disease is among the Beam Therapeutics programs spared, and here the company needs to show differentiation from genetic medicines under FDA review from Vertex Pharmaceuticals and Bluebird Bio. Meanwhile, Beam aims to find partners for its research in allogeneic cancer cell therapies and hepatitis B.

This article seeks to illuminate these pioneering developments and their potential impact on future scientific endeavors of biotechnology and genetics

A MAN was given weeks to live after going to A&E with back pain thinking he had just pulled a muscle.Dylan Lamb, 20, first noticed the problems in

University student Dylan Lamb, 20, thought he had pulled a muscle when he complained of back pain, but was later told he had just weeks to live

Dylan Lamb, 20, who studies international business at the University of Liverpool first noticed the pain in April 2022 before getting painkillers from his GP near his family home in Staffordshire.

{"desktop":[{"injectionEnabled":false,"componentType":"gpt","targeting":{"index":-1,"hivis":"n"},"referenceNode":"header","hideOnSensitiveArticle":true,"hideOnFirstPageView":true,"relativePos":"after","name":"div-gpt-ad-oop-slot","isOOP":true,"type":"outOfPage"},{"componentType":"gpt",&quo...

A 13-year-old girl became the first-ever patient to receive a base-editing therapy, and her leukemia went into remission. Here's how it works.

After six months of treatment, the cancer was gone, it was undetectable but doctors are still monitoring Alyssa in case it comes back